Cargando…

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy

Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zděblová Čermáková, Zuzana, Hurník, Pavel, Konvalinka, David, Štembírek, Jan, Paračková, Tereza, Resová, Kamila, Cvek, Jakub, Blažek, Tomáš, Knybel, Lukáš, Formánek, Martin, Gachechiladze, Mariam, Joerger, Markus, Soltermann, Alex, Škarda, Jozef, Motyka, Oldřich, Janoutová, Jana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958932/
https://www.ncbi.nlm.nih.gov/pubmed/36837562
http://dx.doi.org/10.3390/medicina59020361
_version_ 1784895147466555392
author Zděblová Čermáková, Zuzana
Hurník, Pavel
Konvalinka, David
Štembírek, Jan
Paračková, Tereza
Resová, Kamila
Cvek, Jakub
Blažek, Tomáš
Knybel, Lukáš
Formánek, Martin
Gachechiladze, Mariam
Joerger, Markus
Soltermann, Alex
Škarda, Jozef
Motyka, Oldřich
Janoutová, Jana
author_facet Zděblová Čermáková, Zuzana
Hurník, Pavel
Konvalinka, David
Štembírek, Jan
Paračková, Tereza
Resová, Kamila
Cvek, Jakub
Blažek, Tomáš
Knybel, Lukáš
Formánek, Martin
Gachechiladze, Mariam
Joerger, Markus
Soltermann, Alex
Škarda, Jozef
Motyka, Oldřich
Janoutová, Jana
author_sort Zděblová Čermáková, Zuzana
collection PubMed
description Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified—HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.
format Online
Article
Text
id pubmed-9958932
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99589322023-02-26 HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy Zděblová Čermáková, Zuzana Hurník, Pavel Konvalinka, David Štembírek, Jan Paračková, Tereza Resová, Kamila Cvek, Jakub Blažek, Tomáš Knybel, Lukáš Formánek, Martin Gachechiladze, Mariam Joerger, Markus Soltermann, Alex Škarda, Jozef Motyka, Oldřich Janoutová, Jana Medicina (Kaunas) Article Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified—HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant. MDPI 2023-02-14 /pmc/articles/PMC9958932/ /pubmed/36837562 http://dx.doi.org/10.3390/medicina59020361 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zděblová Čermáková, Zuzana
Hurník, Pavel
Konvalinka, David
Štembírek, Jan
Paračková, Tereza
Resová, Kamila
Cvek, Jakub
Blažek, Tomáš
Knybel, Lukáš
Formánek, Martin
Gachechiladze, Mariam
Joerger, Markus
Soltermann, Alex
Škarda, Jozef
Motyka, Oldřich
Janoutová, Jana
HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
title HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
title_full HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
title_fullStr HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
title_full_unstemmed HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
title_short HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
title_sort hpv and rad51 as prognostic factors for survival in inoperable oral and oropharyngeal cancer in patients unfit for chemotherapy treated with hyperfractionated radiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958932/
https://www.ncbi.nlm.nih.gov/pubmed/36837562
http://dx.doi.org/10.3390/medicina59020361
work_keys_str_mv AT zdeblovacermakovazuzana hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT hurnikpavel hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT konvalinkadavid hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT stembirekjan hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT parackovatereza hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT resovakamila hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT cvekjakub hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT blazektomas hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT knybellukas hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT formanekmartin hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT gachechiladzemariam hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT joergermarkus hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT soltermannalex hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT skardajozef hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT motykaoldrich hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy
AT janoutovajana hpvandrad51asprognosticfactorsforsurvivalininoperableoralandoropharyngealcancerinpatientsunfitforchemotherapytreatedwithhyperfractionatedradiotherapy